Newsfeeds - Spark Newswire

1 minute read

AT&T, Merck And This Leading Payments Processor Stock On CNBC’s ‘Final Trades’

Today, 5:46 AM

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Visa Inc. (NYSE: V), which is down just 5% this year, and has high free cash flow yields

ETH

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 5:46 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

1 minute read

CNBC Halftime Report Final Trades: Visa, AT&T & Merck & Company

By Benzinga Newsdesk

Today, 5:46 AM

- CNBC

MRK

5 minute read

Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

By Shanthi Rexaline

Today, 5:46 AM

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

BGNE

4 minute read

Meta Settles Cambridge Analytica Scandal Case, Microsoft Files Rebuttal To FTC’s Lawsuit Against Activision Deal, US Winter Storm Snaps Holiday Plans: Today’s Top Stories

By Vandana Singh

Today, 5:46 AM

Reuters

$BNB

1 minute read

Merck COVID Antiviral Does Not Reduce Risk Of Hospitalization, Death Rates In Vaccinated Individuals

By Vandana Singh

Today, 5:46 AM

According to a large study, dubbed PANORAMIC, Merck & Co Inc’s (NYSE: MRK) COVID-19 antiviral molnupiravir speeds up recovery but does…

MRK

1 minute read

Merck, Kelun-Biotech Ink Licensing Pact For Seven Cancer Candidates

By Vandana Singh

Today, 5:46 AM

Merck & Co Inc (NYSE:MRK) and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co Ltd) have entered into an exclusive license and collaboration…

MRK

1 minute read

After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm

By Vandana Singh

Today, 5:46 AM

Merck & Co Inc (NYSE:MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ:NGM) that it will not exercise its option to license NGM621 and…

MRK

1 minute read

Europe Approves AstraZeneca’s Two Combo Therapies For Prostate, Bile Duct Cancer Settings

By Vandana Singh

Today, 5:46 AM

The European Commission has approved AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc’s (NYSE:MRK) Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for…

AZN

1 minute read

AstraZeneca Announced Earlier Lynparza Approved in EU for Prostate Cancer; AstraZeneca to Receive $105M Milestone Payment from Merck

By Charles Gross

Today, 5:46 AM

AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated.

AZN